Marina Baretti
Overview
Explore the profile of Marina Baretti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
625
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baretti M, Shekhar S, Sahai V, Shu D, Howe K, Gunchick V, et al.
Hepatol Commun
. 2025 Feb;
9(3).
PMID: 39969434
Background: Intrahepatic cholangiocarcinoma (iCCA) may be genomically subclassified by the presence of potentially actionable molecular aberrations, of which pathogenic alterations in isocitrate dehydrogenase (IDH)1 and fibroblast growth factor receptor (FGFR)2...
2.
Alden S, Charmsaz S, Li H, Tsai H, Danilova L, Munjal K, et al.
J Immunother Cancer
. 2025 Jan;
13(1).
PMID: 39832896
Background: Obesity is a risk factor for developing cancer but is also associated with improved outcomes after treatment with immune checkpoint inhibitors (ICIs), a phenomenon called the obesity paradox. To...
3.
Zabransky D, Kartalia E, Lee J, Leatherman J, Charmsaz S, Young S, et al.
Hepatology
. 2024 Dec;
PMID: 39626209
Background And Aims: Isocitrate dehydrogenase 1 ( IDH1 )-mutant cholangiocarcinoma (CCA) is a highly lethal subtype of hepatobiliary cancer that is often resistant to immune checkpoint inhibitor therapies. We evaluated...
4.
Baretti M, Danilova L, Durham J, Betts C, Cope L, Sidiropoulos D, et al.
Nat Commun
. 2024 Nov;
15(1):9801.
PMID: 39532835
Pancreatic ductal adenocarcinoma (PDA) is characterized by low cytotoxic lymphocytes, abundant immune-suppressive cells, and resistance to immune checkpoint inhibitors (ICI). Preclinical PDA models showed the HDAC inhibitor entinostat reduced myeloid...
5.
Shu D, Ho W, Kagohara L, Girgis A, Shin S, Danilova L, et al.
Nat Immunol
. 2024 Oct;
25(11):2110-2123.
PMID: 39455893
Tertiary lymphoid structures (TLS) are associated with improved response in solid tumors treated with immune checkpoint blockade, but understanding of the prognostic and predictive value of TLS and the circumstances...
6.
DAlessio A, Stefanini B, Blanter J, Adegbite B, Crowley F, Yip V, et al.
Lancet Oncol
. 2024 Oct;
25(11):1465-1475.
PMID: 39437804
Background: Neoadjuvant use of immune checkpoint inhibitors (ICIs) before liver resection results in pathological tumour regression in patients with hepatocellular carcinoma. We aimed to describe the characteristics of pathological responses...
7.
Kao C, Charmsaz S, Alden S, Brancati M, Li H, Balaji A, et al.
J Clin Invest
. 2024 Oct;
134(20).
PMID: 39403935
BACKGROUNDImmune-related adverse events (irAEs) and their associated morbidity/mortality are a key concern for patients receiving immune checkpoint inhibitors (ICIs). Prospective evaluation of the drivers of irAEs in a diverse pan-tumor...
8.
Nakazawa M, Fang M, Vong T, Zorzi J, Griffith P, Anders R, et al.
Cancer Res Commun
. 2024 Aug;
4(8):2123-2132.
PMID: 39142659
Significance: Surgical resection for localized HCC is typically only reserved for those with solitary tumors without vascular invasion. In this retrospective analysis, we show that neoadjuvant immunotherapy may allow high-risk...
9.
Hallab E, Yarchoan M, Baretti M
Cureus
. 2024 Aug;
16(7):e64156.
PMID: 39119399
Fibrolamellar hepatocellular carcinoma (FLC) is a rare form of primary liver cancer that predominantly affects adolescents and young adults with no history of cirrhosis. Surgical resection is a potentially curative...
10.
Mohseni A, Baghdadi A, Madani S, Shahbazian H, Mirza-Aghazadeh-Attari M, Borhani A, et al.
Abdom Radiol (NY)
. 2024 Mar;
49(8):2595-2605.
PMID: 38546828
Purpose: To evaluate the potential of volumetric imaging in predicting survival of advanced hepatocellular carcinoma (HCC) patients receiving immunotherapy. Methods: Retrospective analysis included 40 patients with advanced HCC who received...